Lancet Infectious Diseases

Article	Citations
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study	1264
A minimal common outcome measure set for COVID-19 clinical research	1154
A clinical case definition of post-COVID-19 condition by a Delphi consensus	1112
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial	1050
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study	938
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics	931
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study	897
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial	891
Real estimates of mortality following COVID-19 infection	856
Clinical features and management of human monkeypox: a retrospective observational study in the UK	757
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study	723
Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study	648
The value of antimicrobial peptides in the age of resistance	637
Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study	628
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	579
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance	568
COVID-19 and multisystem inflammatory syndrome in children and adolescents	565
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study	558
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study	535
Genomic evidence for reinfection with SARS-CoV-2: a case study	512
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study	474
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study	463
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2	461
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, mult	445
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study	437

COVID-19 and medical education	416
A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation	413
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical	404
Stigma during the COVID-19 pandemic	382
Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series	355
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries	350
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study	350
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study	343
The many estimates of the COVID-19 case fatality rate	341
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2	335
Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study	334
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study	332
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis	316
The COVID-19 infodemic	305
Exaggerated risk of transmission of COVID-19 by fomites	302
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison	301
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial	301
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression	300
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study	284
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial	257
Serology testing in the COVID-19 pandemic response	250
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people	249
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study	248
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data	244
Smell and taste dysfunction in patients with COVID-19	242
Scaling up COVID-19 rapid antigen tests: promises and challenges	239
Long-term consequences of COVID-19: research needs	239
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study	236
SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England	235
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised	232
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial	230
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT	228
Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study	223
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial	223
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis	217
Willingness to vaccinate against COVID-19 in Australia	216
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-cont	212
Connecting clusters of COVID-19: an epidemiological and serological investigation	210
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical tri	203
COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study	202
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study	201
The global incidence and diagnosis of fungal keratitis	199
Monitoring approaches for health-care workers during the COVID-19 pandemic	194
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	194
Intention to vaccinate against COVID-19 in Australia	192
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study	191
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis	191
The indirect impact of COVID-19 on women	190
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and	185
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis	185

Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design	184
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study	181
The important role of serology for COVID-19 control	178
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5	177
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial	175
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial	173
What reinfections mean for COVID-19	168
Global shortage of personal protective equipment	167
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study	167
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis	165
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wav	165
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis	163
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	162
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity	161
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard	161
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding	160
Baricitinib for COVID-19: a suitable treatment?	160
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19	156
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study	155
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study	154
Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study	151
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review	150
Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis	149
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis	146
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study	145
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study	142
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies	142
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	141
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial	140
Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US	138
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England	136
Monkeypox outbreaks outside endemic regions: scientific and social priorities	136
Prevention of monkeypox with vaccines: a rapid review	134
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study	133
Monoclonal antibody therapies against SARS-CoV-2	133
China's successful control of COVID-19	132
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial	130
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study	127
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial	126
Bell's palsy and SARS-CoV-2 vaccines	125
Concerns and motivations about COVID-19 vaccination	125
SARS-CoV-2 and the human-animal interface: outbreaks on mink farms	124
Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective obse	124
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB	123
Hospitalisation among vaccine breakthrough COVID-19 infections	121
Vaccinology: time to change the paradigm?	117
Low risk of SARS-CoV-2 transmission by fomites in real-life conditions	117
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled	117
Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2	116
Estimating case fatality rates of COVID-19	115
Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and An	113
Protective immunity after recovery from SARS-CoV-2 infection	113
Tracking the 2022 monkeypox outbreak with epidemiological data in real-time	112
Omicron sublineage BQ.1.1 resistance to monoclonal antibodies	111
SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study	111
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study	111
RT-PCR for SARS-CoV-2: quantitative versus qualitative	110
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial	109
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation	108
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study	108
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe	106
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2	106
New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial	105
The urgent need for metallo-β-lactamase inhibitors: an unattended global threat	105
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (CO	105
Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study	104
ChatGPT and antimicrobial advice: the end of the consulting infection doctor?	104
Genomic-informed pathogen surveillance in Africa: opportunities and challenges	103
Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant	101
BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial	100
Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review	100
Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis	100
Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study	99
Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure	99
100 years of Mycobacterium bovis bacille Calmette-Guérin	98
Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study	97
SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series	96
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study	96
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial	95
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland	95

Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study	95
Global burden and trends of sexually transmitted infections from 1990 to 2019: an observational trend study	92
Hand hygiene in health care: 20 years of ongoing advances and perspectives	92
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study	91
The world's largest COVID-19 vaccination campaign	90
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial	90
The place for remdesivir in COVID-19 treatment	89
Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study	88
Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM	88
Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis	88
Long COVID in the skin: a registry analysis of COVID-19 dermatological duration	87
Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant	87
Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant	86
Lung fibrosis: an undervalued finding in COVID-19 pathological series	85
Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort	85
COVID-19 human challenge studies: ethical issues	85
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5	84
The importance of understanding the infectious microenvironment	84
Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis	83
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study	83
Viral loads in clinical samples of men with monkeypox virus infection: a French case series	82
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial	81
Review of 2022 WHO guidelines on the control and elimination of schistosomiasis	81
Hydroxychloroquine prophylaxis for COVID-19 contacts in India	80
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3	79
First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020	79
Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study	79
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation	78
Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86	78
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	77
The intersection of COVID-19 and mental health	77
Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial	77
Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019	76
Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study	75
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study	75
Chloroquine or hydroxychloroquine for prophylaxis of COVID-19	74
Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study	74
Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study	74
Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis	74
Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective	74
The scientific and ethical feasibility of immunity passports	74
Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial	74
Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy s	74
Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis	72
Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study	72
Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark	71
Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis	71
Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study	70
Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controll	69
Virological characteristics of the SARS-CoV-2 JN.1 variant	69
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac	68
The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned	67
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	67
SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21	67
Case isolation, contact tracing, and physical distancing are pillars of COVID-19 pandemic control, not optional choices	66
Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study	66
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	65
COVID-19 vaccine equity and booster doses	65
Antibiotic prescribing in general practice during COVID-19	65
Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak	64
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study	64
Global increases in antibiotic consumption: a concerning trend for WHO targets	63
Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant	63
CoronaVac induces lower neutralising activity against variants of concern than natural infection	63
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study	63
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccinati	63
Persistence of IgG response to SARS-CoV-2	63
The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation	63
Long COVID: tackling a multifaceted condition requires a multidisciplinary approach	62
Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants	62
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study	61
Quantifying the global number of tuberculosis survivors: a modelling study	61
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial	61
Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain	61
The origin of SARS-CoV-2	61
Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019	60
Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a cross-sectional analysis	60
Hospitalisation associated with SARS-CoV-2 delta variant in Denmark	60
A case of SARS-CoV-2 reinfection in Ecuador	59
Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial	58
Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens	58
Prevention of host-to-host transmission by SARS-CoV-2 vaccines	58
Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate	58
Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies	58
Associations between phone mobility data and COVID-19 cases	57
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negati	57
Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases	57
Global incidence and mortality of severe fungal disease	57
Why we need a deeper understanding of the pathophysiology of long COVID	56
Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial	56
Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity	56
Global COVID-19 vaccine inequity	56
Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection	56
Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology a	55
25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward	55